Actively Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-05-11
310
Participants Needed
41
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
CONDITIONS
Official Title
A Study of BG-C477 in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must sign the informed consent form and be able to provide written consent
- Participants must agree to provide an archival tumor tissue sample or fresh baseline biopsy
- Phase 1a: Participants with histologically confirmed advanced, metastatic, or unresectable solid tumors previously treated with at least 2 lines of standard systemic therapy or with no standard treatment available
- Phase 1b Part A: Participants with histologically confirmed advanced or metastatic select solid tumors previously treated with and progressed after at least 1 line of standard systemic therapy
- Phase 1b Part B: Participants with histologically confirmed advanced or metastatic select solid tumors who have received 0 or 1 line of systemic therapy for advanced disease
- At least 1 measurable lesion as assessed by RECIST v1.1
- Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 or less
- Adequate organ function
- Female participants of childbearing potential must agree to use highly effective birth control and avoid egg donation during the study and for specified months after last doses of study drugs
- Nonsterile male participants must agree to use highly effective birth control and avoid sperm donation during the study and for specified months after last doses of study drugs
You will not qualify if you...
- Prior treatment with any carcinoembryonic antigen-targeted antibody drug conjugates or ADCs containing topoisomerase 1 inhibitor as payload
- History of severe allergic reactions, severe infusion reactions, or hypersensitivity to the study drugs or similar protein-based therapies
- Active leptomeningeal disease or uncontrolled, untreated brain metastases
- Any other malignancy within 2 years before the first dose of study drugs, except the cancer under study or certain locally treated cancers
- Other protocol-defined criteria may also apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 41 locations
1
City of Hope Phoenix Cancer Center
Goodyear, Arizona, United States, 85338
Actively Recruiting
2
City of Hope National Medical Center
Duarte, California, United States, 91010-3012
Actively Recruiting
3
Yale University, Yale Cancer Center
New Haven, Connecticut, United States, 06520-8028
Actively Recruiting
4
The University of Kansas Cancer Center
Westwood, Kansas, United States, 66205-2003
Actively Recruiting
5
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601-2191
Actively Recruiting
6
The University of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Actively Recruiting
7
Texas Oncology Longview
Longview, Texas, United States, 75601
Actively Recruiting
8
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia, NSW 2148
Actively Recruiting
9
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia, NSW 2086
Actively Recruiting
10
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia, QLD 4575
Actively Recruiting
11
Cancer Research South Australia
Adelaide, South Australia, Australia, SA 5000
Actively Recruiting
12
The Alfred Hospital
Melbourne, Victoria, Australia, VIC 3004
Actively Recruiting
13
One Clinical Research
Nedlands, Western Australia, Australia, WA 6009
Actively Recruiting
14
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
15
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 101149
Actively Recruiting
16
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
17
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
18
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
19
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
20
Guangxi Medical University Cancer Hospital Wuxiang Branch
Nanning, Guangxi, China, 530201
Actively Recruiting
21
Jiamusi Cancer Hospital
Jiamusi, Heilongjiang, China, 154004
Actively Recruiting
22
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Actively Recruiting
23
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450052
Actively Recruiting
24
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
25
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Actively Recruiting
26
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
27
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
28
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, China, 332000
Actively Recruiting
29
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001
Actively Recruiting
30
Jining No1 Peoples Hospital East Branch
Jining, Shandong, China, 272002
Actively Recruiting
31
Linyi Peoples Hospital Beicheng Branch
Linyi, Shandong, China, 276005
Actively Recruiting
32
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
33
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
34
Yunnan Cancer Hospital
Kunming, Yunnan, China, 650100
Actively Recruiting
35
The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
Hangzhou, Zhejiang, China, 310002
Actively Recruiting
36
Taizhou Hospital of Zhejiang Province (East)
Taizhou, Zhejiang, China, 317004
Actively Recruiting
37
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325000
Actively Recruiting
38
Kansai Medical University Hospital
Hirakata, Osaka, Japan, 573-1191
Actively Recruiting
39
Cancer Institute Hospital of Jfcr
Kotoku, Tokyo, Japan, 135-8550
Actively Recruiting
40
Auckland City Hospital
Auckland, New Zealand, 1023
Actively Recruiting
41
Siriraj Hospital
Bangkok, Thailand, 10700
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here